Akamis Bio (formerly known as PsiOxus Therapeutics) is a company that develops cancer immunotherapies. Its T-SIGn platform uses viral vector-based tumor gene therapies to target solid tumors through intravenous delivery. The platform addresses immune evasion mechanisms, including reduced tumor antigen presentation, local immunosuppression, and stromal barriers, with applications in monotherapy or combination therapies in oncology.